TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers report that the mitochondrial protein Miro1 was elevated in skeletal muscle from people with type 2 diabetes and impaired muscle insulin response in experimental work. Removing Miro1 restored insulin responsiveness in preclinical models, while an exercise trial found lower muscle Miro1 alongside improved insulin sensitivity; a Miro1-targeted treatment has not been tested in people.
Researchers have identified Miro1, a protein on the outer membrane of mitochondria, as a possible contributor to muscle insulin resistance, a central feature of type 2 diabetes. In findings published in Nature Communications, removing Miro1 restored insulin responsiveness in preclinical models, while a trial in people with obesity and type 2 diabetes found that exercise lowered muscle Miro1 levels alongside improved insulin sensitivity.
The research team examined Miro1 in laboratory cells, preclinical models and people with type 2 diabetes. The protein was present at higher levels in skeletal muscle from people with the disease. In experimental work, excess Miro1 was associated with a weaker muscle response to insulin, which helps the body regulate blood sugar.
When researchers removed Miro1 in preclinical models, muscle insulin responsiveness returned. That result supports a direct role for the protein in the experimental systems studied, but it does not establish that reducing Miro1 would be safe or effective as a treatment in people.
The human component was a randomized controlled trial involving participants with obesity and type 2 diabetes. Researchers compared aerobic exercise with standard medical care. Participants assigned to exercise had lower muscle Miro1 levels, alongside improvements in insulin sensitivity and the muscles’ capacity to produce energy. The report does not establish that the change in Miro1 caused those improvements.
A Possible Link Between Muscle and Insulin
The findings offer a possible molecular explanation for how changes inside muscle cells may contribute to insulin resistance. Skeletal muscle is a key site where the body responds to insulin, so identifying a protein associated with a weaker response could give researchers a specific pathway to investigate.
The exercise result also connects a change in muscle biology with an intervention already studied in people with diabetes. The researchers say lower Miro1 may be one mechanism behind exercise-related improvements in insulin sensitivity. The trial findings do not show that Miro1 is the sole mechanism, or that deliberately lowering it would reproduce exercise’s broader effects.
For now, the work points to a research target, not a new therapy. Any treatment aimed at Miro1 would need further testing for its effects and safety in people, and would not be established as a replacement for existing diabetes care.
Products Worth Considering
Withings Sleep – Sleep Tracking Pad Under the Mattress
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Garmin Forerunner 935 GPS Running and Multisport Watch, Black
As an affiliate, we earn on qualifying purchases.
From Mitochondria to Muscle Response
Miro1, short for mitochondrial Rho GTPase 1, is located on the outer membrane of mitochondria, the structures inside cells that produce energy. The researchers investigated whether elevated levels of the protein could affect muscle function and the response to insulin.
The study’s approach moved across laboratory experiments, preclinical models and a human exercise trial. Those stages provide different kinds of evidence: experiments in models can test mechanisms, while the human trial shows whether exercise-related changes in Miro1 occur in participants. The human findings do not amount to a trial of a drug that targets the protein.
Senior author John P. Kirwan conducted the research while at LSU’s Pennington Biomedical Research Center and has since moved to the University of Oklahoma’s Harold Hamm Diabetes Center. The report says he plans to continue this research there, combining laboratory work with studies involving people.
““This study, the product of years of work, identifies Miro1 as a key part of the answer.””
— John P. Kirwan, the study’s senior author
Treatment Potential Remains Untested
The findings do not show that a drug targeting Miro1 can improve diabetes outcomes. The reported restoration of insulin responsiveness followed Miro1 removal in preclinical models; the human trial tested exercise, not a Miro1-targeting treatment.
It is also not clear from the report how large or long-lasting the changes in Miro1 were, or whether they occurred across a broader range of people with type 2 diabetes. The association between lower Miro1 and better insulin sensitivity in the exercise group does not by itself prove that the protein change caused the improvement. Further research is needed to establish the protein’s role and whether it can be safely targeted.
Further Studies at Oklahoma Center
Kirwan plans to continue investigating Miro1 at the Harold Hamm Diabetes Center, using laboratory experiments and studies involving people to examine the biological processes behind diabetes. The next questions include how Miro1 affects muscle insulin response, whether its levels can be altered safely, and whether such changes produce meaningful benefits for patients.
Until those studies are reported, the research supports Miro1 as a possible target for investigation rather than a ready treatment. The team’s next findings will help clarify whether the protein’s role in preclinical experiments translates into a practical approach to care.
Key Questions
What is Miro1?
Miro1 is a protein located on the outer membrane of mitochondria, the energy-producing structures inside cells. The study examined its possible role in muscle response to insulin.
Did the study prove that Miro1 causes type 2 diabetes?
No. The study linked higher muscle Miro1 to impaired insulin response and found that removing the protein restored responsiveness in preclinical models. It does not establish that Miro1 alone causes type 2 diabetes in people.
What did the exercise trial find?
Among participants with obesity and type 2 diabetes, the exercise group had lower muscle Miro1 levels alongside improved insulin sensitivity and muscle energy-producing capacity. The trial did not test a drug targeting Miro1.
Is there a treatment that targets Miro1?
The report describes Miro1 as a possible future research target, not an available or proven treatment. Safe and effective ways to target the protein in people have not been established.
Source: sciencedaily.com
